

Cutaquig SCIG Therapy Patient Referral and Prescription

То:		From:			Phone:			
Intake phone: 800.814.0992		Fax:			Number of Pages (Including Co			ling Cover):
· ·	OOB:		Allerg	jies:			<u> </u>	<u> </u>
Patient Name:			Height	:			Weight:	
 Begin Cutaquig SCIG per KabaFusion protocol formonths Begin Cutaquiggrams SCIG everyformonths KabaFusion to provide infusion pump needle administration sets (A4221) KabaFusion to provide infusion supplies for infusion pump (K0552) KabaFusion to provide mechanical ambulatory infusion pump (E0779) Infusion RN home visit prior to therapy start to assess patient and home environment, educate patient about SCIG therapy. Infusion RN visits x 3 and PRN to educate patient to self administer Cutaquig infusion KabaFusion to provide all professional services related to infusion 								
Diagnosis:								ICD-10
Common Variable Immunodeficiency with Predominant Immunoregulatory T-Cell Disorders								D83.1
								D82.0
Combined Immunodeficiency, Unspecified								D81.9
Severe Combined Immunodeficiency [SCID] with Low T- and B- Cell Numbers								D81.1
Severe combined Immunodeficiency [SCID] with Low or Normal B-Cell Numbers								D81.2
Selective deficiency of Immunoglobulin A IgA]								D80.2
Selective deficiency of Immunoglobulin A IgA]								D80.2
Selective deficiency of Immunoglobulin M [IgM]								D80.3
Hereditary Hypogammaglobulinemia								D80.0
Immunodeficiency with Increased IgM								D80.5
Other Common Variable Immunodeficiencies								D83.8
Common Variable Immunodeficiency, Unspecified								D83.9
Other: D83.9								
Premedication Orders:				DIPHENH	YDRAMI	NE 25 N	IG orally PRE	E-SCIG
Refill x 1Year				Other:			j	
Per KabaFusion recommendation: Epinephrine 0.3mg 2-Pak Auto-Injector ACETAMINOPHEN 650 MG (325mg X 2) orally PRE-SCIG None							or	
Prescriber Signature:Date								
Print Prescriber Name:NPI#								
Please fax the following information: Immunoglobulin order – include dose, route of administration, frequency, duration, and any pre-medications OR use prescription order section above Patient demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise H & P OR progress note(s) describing diagnosis and clinical status Labs – BUN/Creatinine (preferred within last 90 days), ImmunoglobulinPanel CONFIDENTIALITY NOTICE The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. No rights in, relating and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachments, the subject to obligation Pharmacy 241 Winton M. Blount Loop Montgomery, AL 36117								
Phone: 800.814.0992 Fax: 334.279.7032 www.kabafusion.com								